13
Participants
Start Date
August 15, 2019
Primary Completion Date
September 3, 2024
Study Completion Date
September 3, 2024
ATL001
ATL001 infusion
Checkpoint Inhibitor
Nivolumab
Instituto de Investigación Sanitaria Fundación Jimenez Díaz, Madrid
Centro Integral Oncologico Clara Campal (CIOCC) Hospital Universitario HM Sanchinarro, Madrid
Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Cambridge
University College London Hospitals (UCLH) NHS Foundation Trust, University College Hospital, London
Royal Free London NHS Foundation Trust, Royal Free Hospital, London
Guys and St Thomas' NHS Foundation Trust, Guy's Hospital, London
The Royal Marsden NHS Foundation Trust, The Royal Marsden Hospital, London
The Christie NHS Foundation Trust, Christie Hospital, Manchester
The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne
University Hospital Southampton NHS Foundation Trust, Southampton General Hospital, Southampton
Lead Sponsor
Achilles Therapeutics UK Limited
INDUSTRY